Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Briacell Therapeutics Corp WT (BCTXW)

Briacell Therapeutics Corp WT (BCTXW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer

/PRNewswire/ -- USA News Group - Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs being labeled as landmark in...

BCTXW : 0.2700 (-21.26%)
ONC.TO : 1.37 (unch)
BCT.TO : 1.35 (-11.18%)
ONCY : 1.0050 (-0.50%)
CTMX : 1.2900 (-3.01%)
BCTX : 0.9501 (-15.17%)
RLAY : 6.79 (-1.59%)
HOLX : 71.56 (-1.27%)
IPA’s Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies

IPA (IMMUNOPRECISE ANTIBODIES LTD.) ( “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that BioStrand BV (“BioStrand”), an AI in silico discovery...

BCTX : 0.9501 (-15.17%)
BCTXW : 0.2700 (-21.26%)
IPA : 0.9999 (+0.94%)
BCT.TO : 1.35 (-11.18%)
BriaCell Secures License for a Promising Novel Anti-Cancer Agent

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 04, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...

BCTXW : 0.2700 (-21.26%)
BCTX : 0.9501 (-15.17%)
BCT.TO : 1.35 (-11.18%)
BriaCell Partners with Waisman Biomanufacturing to Manufacture and Supply Prostate Cancer Immunotherapy

Extended survival and tumor shrinkage in advanced breast cancer patients who matched the immunotherapy HLA types, lead to the development of BriaCell’s...

BCTXW : 0.2700 (-21.26%)
BCTX : 0.9501 (-15.17%)
BCT.TO : 1.35 (-11.18%)
BriaCell Enters Research Agreement to Identify Novel Targets for Cancer Treatment

PHILADELPHIA and VANCOUVER, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...

BCTXW : 0.2700 (-21.26%)
BCTX : 0.9501 (-15.17%)
BCT.TO : 1.35 (-11.18%)
BriaCell Anti-Cancer Technology Published in Leading Cancer Drug Discovery Journal

Anti-Cancer activity of BriaCell’s lead candidate, Bria-IMT™, in advanced breast cancer patients was published in a leading peer-reviewed publication....

BCTXW : 0.2700 (-21.26%)
BCTX : 0.9501 (-15.17%)
BCT.TO : 1.35 (-11.18%)
BriaCell Adds Additional Clinical Sites to Broaden Patient Access and Further Boost Enrollment

PHILADELPHIA and VANCOUVER, British Columbia, May 18, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...

BCTXW : 0.2700 (-21.26%)
BCTX : 0.9501 (-15.17%)
BCT.TO : 1.35 (-11.18%)
BriaCell Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy

U.S. Food and Drug Administration (FDA) has granted Fast Track status to BriaCell’s lead candidate, Bria-IMT™, for the treatment of metastatic breast...

BCTXW : 0.2700 (-21.26%)
BCTX : 0.9501 (-15.17%)
BCT.TO : 1.35 (-11.18%)
BriaCell Presents Development Details of Bria-OTS™ Platform Technology at the American Association for Cancer Research (AACR) Annual Meeting 2022

Based on clinical data with Bria-IMT™, BriaCell has developed Bria-OTS™, an off-the-shelf (i.e. pre-manufactured) personalized immunotherapy.Bria-OTS™ will...

BCTXW : 0.2700 (-21.26%)
BCTX : 0.9501 (-15.17%)
BCT.TO : 1.35 (-11.18%)
BriaCell advances preparatory work for new Bria-OTS™ breast cancer clinical trial

Bria-OTS™ would build on BriaCell’s existing clinical trial data with Bria-IMT™, treating each patient with the optimized pre-manufactured Bria-OTS™...

BCTXW : 0.2700 (-21.26%)
BCTX : 0.9501 (-15.17%)
BCT.TO : 1.35 (-11.18%)

Barchart Exclusives

Should You Invest in Dell and Super Micro for More xAI Upside?
AI server stocks, including Dell and Super Micro Computer, remain solid investment choices in 2024, despite their stellar gains in the last 18 months. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar